Analysts Offer Insights on Healthcare Companies: G1 Therapeutics Inc (NASDAQ: GTHX) and Geron Corp (NASDAQ: GERN)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on G1 Therapeutics Inc (GTHXResearch Report) and Geron Corp (GERNResearch Report) with bullish sentiments.

G1 Therapeutics Inc (GTHX)

In a report released yesterday, Harshita Polishetty from B.Riley FBR reiterated a Buy rating on G1 Therapeutics Inc, with a price target of $55.00. The company’s shares closed last Monday at $23.04.

According to TipRanks.com, Polishetty is a 3-star analyst with an average return of 3.9% and a 38.5% success rate. Polishetty covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Karyopharm Therapeutics.

Currently, the analyst consensus on G1 Therapeutics Inc is a Strong Buy with an average price target of $65.20, which is a 181.3% upside from current levels. In a report issued on September 24, Needham also reiterated a Buy rating on the stock with a $74.00 price target.

See today’s analyst top recommended stocks >>

Geron Corp (GERN)

In a report released today, George Zavoico from B.Riley FBR maintained a Buy rating on Geron Corp, with a price target of $4.50. The company’s shares closed last Monday at $1.50.

According to TipRanks.com, Zavoico has 0 stars on 0-5 star ranking scale with an average return of -11.5% and a 35.5% success rate. Zavoico covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Acasti Pharma, Inc., and BioLife Solutions.

Geron Corp has an analyst consensus of Strong Buy, with a price target consensus of $4.17.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.